Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics
Author: Van Sebille, Y.
Stansborough, R.
Wardill, H.
Bateman, E.
Gibson, R.
Keefe, D.
Citation: Current Oncology Reports, 2015; 17(11):50-1-50-8
Publisher: Springer
Issue Date: 2015
ISSN: 1523-3790
Statement of
Ysabella Z. A. Van Sebille, Romany Stansborough, Hannah R. Wardill, Emma Bateman, Rachel J. Gibson, Dorothy M. Keefe
Abstract: Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
Keywords: Mucositis; Toxicity; Chemotherapy-induced gut toxicity; Cancer side effects; Zinc sulphate; Palifermin; R-spondin1; Benzydamine hydrochloride (HCl); Probiotics; Antimicrobials; Antioxidants; Analgesics; Coating agents; Mucositis treatment
Description: This article is part of the Topical Collection on Palliative Medicine
Rights: © Springer Science+Business Media New York 2015
RMID: 0030036496
DOI: 10.1007/s11912-015-0474-9
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.